The appraisal states that there is good evidence from longterm studies that these drugs can improve the quality of life of people with Alzheimer disease
The appraisal recommends that memantine is a good option for all patients with Alzheimer disease
The appraisal says that donepezil, galantamine, and rivastigmine should be reserved only for people with Alzheimer disease of moderate severity (i.e., those with a Mini-Mental State Examination (MMSE) score between ten and 20) 
Answer 2. 76%
Implementation of the 2003 European guidelines on cardiovascular disease prevention would label an astonishing 76% of Norwegian adults as having unfavorably high cholesterol and/or blood pressure levels [1] . Iona Heath notes that there has been a "continual lowering of thresholds for treatment of blood pressure and lipids" [2] . She has expressed great concern that seven of ten people in the British population are now taking medications for preventing or treating illness [3] .
Answer 3. US$85 million
A market analyst reports that drug companies spent US$85 million on unbranded direct-to-consumer advertising in Europe in 2004 [1] . Spending is expected to reach US$345.5 million by 2008.
Answer 4. 80%
On its Web site, Pfi zer states, "VIAGRA can work for you. In fact, studies show that VIAGRA works for more than 80% of men with ED [erectile dysfunction] taking VIAGRA 100 mg versus 24% of men taking a sugar pill" (http:⁄⁄www.viagra. com/whyViagra/highlyEffective.asp).
Answer 5. 50%-60% of the time A systematic review of the evidence found that the drug probably only results in successful intercourse 50%-60% of the time [1] . Lexchin notes that "this 50%-60% rate is far short of the 'more than 80% of men' that Pfi zer trumpets" [2] .
Answer 6. Men between the ages of 18 and 45 years
Between 1998 and 2002, the group showing the largest increase in Viagra use was men between the ages of 18 and 45, and only one-third of these men had a possible etiologic reason for needing Viagra [1] .
Answer 7. The appraisal says that donepezil, galantamine, and rivastigmine should be reserved only for people with Alzheimer disease of moderate severity (i.e., those with a Mini-Mental State Examination score between ten and 20)
In its latest Appraisal Consultation Document of 23 January 2006 (http:⁄⁄www. nice.org.uk/page.aspx?o=288826), the NICE committee states that "estimates of cost effectiveness could be considered suffi ciently acceptable" to allow the prescribing of donepezil, galantamine, and rivastigmine for people with Alzheimer disease of moderate severity only (i.e., those with an MMSE score between ten and 20). But in their analysis of the clinical trial evidence, Maggini and colleagues found that the treatment effects of these drugs are modest, and that there is evidence of wide variability in the outcomes reported [1] . The NICE committee noted that "the evidence available on the long-term effectiveness of the AChE [acetyl cholinesterase] inhibitors on outcomes of importance to people with Alzheimer's disease and their carers, such as quality of life and delayed time to nursing home placement, was limited and largely inconclusive." The appraisal states that memantine is "not recommended as a treatment option for people with Alzheimer's disease except as part of properly constructed clinical studies." Answer 8. The European Medicines Evaluation Agency refused to approve fl uoxetine for PMDD The European Medicines Evaluation Agency refused to approve fl uoxetine for PMDD, raising concerns that women "with less severe pre-menstrual symptoms might erroneously receive a diagnosis of PMDD resulting in widespread inappropriate short-and long-term use of fl uoxetine" [1] . The US and Australia have approved selective serotonin reuptake inhibitors for PMDD, but the Australian government's Pharmaceutical Benefi ts Scheme does not cover their costs [2] . Soon after the launch of Sarafem in the US, the Food and Drug Administration (FDA) judged a television advert to violate US law because it failed to distinguish clearly between PMDD and premenstrual syndrome [3] .
Answer 9. 43%
Laumann and colleagues, in their analysis of data from the National Health and Social Life Survey-a probability sample study of sexual behavior in a demographically representative 1992 cohort of US adults-reported that 43% of women aged 18-59 years suffer from female sexual dysfunction [1] .
In the BMJ, John Bancroft, former director of the Kinsey Institute, dismissed the notion of a dysfunction affecting 43% of women as "outrageous" [2] . He said that the 43% fi gure "doesn't stand up scientifi cally," and argued that reductions in sexual interest or other problems are often healthy, adaptive responses and "an understandable reaction to adverse conditions in the relationship...or in the individual's general life situation." Because of the diffi culty distinguishing between a genuine dysfunction and a healthy adaptive response, any survey-based estimates of the condition's prevalence are, he said, "unreliable."
Answer 10. Pfi zer attempted to have sildenafi l (Viagra) approved to treat female sexual arousal disorder, but its quest ended because of consistently poor clinical trial results Pfi zer's quest to have Viagra approved to treat female sexual arousal disorder ended because of consistently poor clinical trial results. In its public statement, the company said that several large-scale, placebo-controlled studies, which included about 3,000 women with female sexual arousal disorder, showed inconclusive results on the effi cacy of the drug [1] . Nevertheless, there are reports that Viagra continues to be prescribed off label for women [2] . An FDA advisory panel voted unanimously not to approve Intrinsa, saying that the manufacturer had not provided suffi cient long-term safety data, and questioned the clinical signifi cance of the trials on Intrinsa [3] . Nevertheless, testosterone researcher Jan Shifren estimates that 20% of all the prescriptions of testosterone products approved for men are actually written (off label) for women [4] .
